Beyfortus® – passive immunization against RSV for all children

Photo of author
Written By Rivera Claudia

Lorem ipsum dolor sit amet consectetur pulvinar ligula augue quis venenatis. 

Candidate Galeno 2024

Nirsevimab (Beyfortus®) from Sanofi is the first passive immunization approved against RSV (respiratory syncytial virus) for use in healthy full-term and preterm infants, as well as in infants with underlying medical conditions. The monoclonal antibody only needs to be administered once to prevent lower respiratory tract disease associated with RSV.

Source link

Leave a Comment

data data data data data data data data data data data data data data data data data data data